Rapaflo

Rapaflo is a brand name of silodosin, approved by the FDA in the following formulation(s):

RAPAFLO (silodosin - capsule; oral)

• 
  Manufacturer: WATSON LABS
  
  Approval date: October 8, 2008
  
  Strength(s): 4MG, 8MG ^[RLD]

Has a generic version of Rapaflo been approved?

No. There is currently no therapeutically equivalent version of Rapaflo available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapaflo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  1,5,7-trisubstituted indoline compounds and salts thereof
  Patent 5,387,603
  Issued: February 7, 1995
  Inventor(s): Kitazawa; Makio & Ban; Masaaki & Okazaki; Kosuke & Ozawa; Motoyasu & Yazaki; Toshikazu & Yamagishi; Ryoichi
  Assignee(s): Kissei Pharmaceutical Co., Ltd.
  Indoline compounds represented by the formula: ##STR1## wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R.sup.1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.
  
  Patent expiration dates:
  
  
  • December 1, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Use of .alpha..sub.1C specific compounds to treat benign prostatic hyperlasia
  Patent 5,403,847
  Issued: April 4, 1995
  Inventor(s): Gluchowski; Charles & Forray; Carlos C. & Chiu; George & Branchek; Theresa A. & Wetzel; John M. & Hartig; Paul R.
  Assignee(s): Synaptic Pharmaceutical Corporation
  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
  
  Patent expiration dates:
  
  
  • November 13, 2012
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
  
  



• 
  Use of .alpha..sub.1c specific compounds to treat benign prostatic hyperplasia
  Patent 5,780,485
  Issued: July 14, 1998
  Inventor(s): Gluchowski; Charles & Forray; Carlos C. & Chiu; George & Branchek; Theresa A. & Wetzel; John M. & Hartig; Paul R.
  Assignee(s): Synaptic Pharmaceutical Corporation
  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
  
  Patent expiration dates:
  
  
  • November 13, 2012
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
  
  



• 
  Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
  Patent 6,015,819
  Issued: January 18, 2000
  Inventor(s): Gluchowski; Charles & Forray; Carlos C. & Chiu; George & Branchek; Theresa A. & Wetzel; John M. & Hartig; Paul R.
  Assignee(s): Synaptic Pharmaceutical Corporation
  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
  
  Patent expiration dates:
  
  
  • November 13, 2012
    
    ✓ 
    Patent use: USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 8, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Rapaflo Consumer Information (Drugs.com)
• Rapaflo Consumer Information (Wolters Kluwer)
• Rapaflo Consumer Information (Cerner Multum)
• Rapaflo Advanced Consumer Information (Micromedex)
• Rapaflo AHFS DI Monographs (ASHP)
• Silodosin Consumer Information (Wolters Kluwer)
• Silodosin Consumer Information (Cerner Multum)
• Silodosin Advanced Consumer Information (Micromedex)
• Silodosin AHFS DI Monographs (ASHP)